Navigation Links
PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
Date:3/5/2012

ANNAPOLIS, Md., March 5, 2012 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that management will present at the ROTH 24th Annual OC Growth Stock Conference on Monday, March 12, 2012 at 5:30 pm PT at the Ritz-Carlton Laguna Niguel in Dana Point, CA. Event:

24th Annual ROTH ConferenceDate:

Monday, March 12, 2012 at 5:30 pm Place:

Ritz-Carlton Laguna Niguel, Salon 1Time:

5:30 pm PTAbout PharmAthene, Inc.PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Recombinant BChE - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • In addition, pursuant to an opinion issued September 22, 2011 from the Delaware Court of Chancery, PharmAthene is entitled to 50% of the profits over 10 years from all sales of SIGA Technologies' ST-246, and related products, a novel smallpox antiviral agent being developed by SIGA for the treatment and prevention of morbidity and mortality associated with exposure to the causative agent of smallpox (once SIGA receives the first $40 million in net profits from sales of ST-246.) For more information about PharmAthene, please visit www.PharmAthene.com.


    '/>"/>
    SOURCE PharmAthene, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1

    Related biology technology :

    1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
    2. PharmAthene Reports Third Quarter 2011 Financial and Operating Results
    3. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
    4. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
    5. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
    6. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
    7. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
    8. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
    9. PharmAthene Completes $6.5 Million Registered Direct Offering
    10. PharmAthene Reports First Quarter 2011 Financial and Operating Results
    11. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/25/2016)... ... May 25, 2016 , ... Founder ... double board-certified in surgery and surgery of the hand by the National Board ... stranger to going above and beyond in his pursuit of providing the most ...
    (Date:5/25/2016)... ... May 25, 2016 , ... Scientists at the University of ... tried for mesothelioma may be hampering the research that could lead to one good ... here to read it now. , The team evaluated 98 mesothelioma patients ...
    (Date:5/25/2016)... ... , ... Lady had been battling arthritis since the age of two and ... Lady’s owner Hannah sought the help of Dr Jeff Christiansen of Superior Veterinary ... ligament and help with the pain of Lady’s arthritis. Dr Christiansen suggested that in ...
    (Date:5/24/2016)... , ... May 24, 2016 , ... ... diabetes, and traumatic injuries, will be accelerated by research at Worcester Polytechnic Institute ... engines of wound healing and tissue regeneration. , The novel method, developed by ...
    Breaking Biology Technology:
    (Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
    (Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
    (Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
    Breaking Biology News(10 mins):